Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study.
Chu T, Zhang W, Zhang B, Zhong R, Zhang X, Gu A, Shi C, Wang H, Xiong L, Lu J, Qian J, Zhang Y, Dong Y, Teng J, Gao Z, Wang W, Shen Y, Nie W, Lim JU, Mehta HJ, Neal JW, Lou Y, Xu J, Zhong H, Han B.
Chu T, et al. Among authors: gu a.
Transl Lung Cancer Res. 2022 Jul;11(7):1394-1404. doi: 10.21037/tlcr-22-438.
Transl Lung Cancer Res. 2022.
PMID: 35958322
Free PMC article.